Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Quality of life in adults with growth hormone (GH) deficiency : response to treatment with recombinant human GH in a placebo-controlled 21-month trial

Burman, P LU ; Broman, J E LU ; Hetta, J ; Wiklund, I ; Erfurth, E M LU ; Hagg, E and Karlsson, F A (1995) In The Journal of clinical endocrinology and metabolism 80(12). p.90-3585
Abstract

We examined the effect of GH supplementation on the psychological capacity and sense of well-being in 36 patients with adult-onset GH deficiency (GHD). Recombinant human GH was given in a 21-month cross-over, double blind trial, and quality of life was assessed by using three self-rating questionnaires: the Hopkins Symptom Check List (HSCL), the Nottingham Health Profile (NHP), and the Psychological General Well-Being index. In addition, at the final examination the spouses completed a short questionnaire concerning their partner. Before treatment, the patients had lowered quality of life as determined by the HSCL and NHP inventories, and a correlation between the duration of GHD and the reported symptoms was observed. Upon treatment,... (More)

We examined the effect of GH supplementation on the psychological capacity and sense of well-being in 36 patients with adult-onset GH deficiency (GHD). Recombinant human GH was given in a 21-month cross-over, double blind trial, and quality of life was assessed by using three self-rating questionnaires: the Hopkins Symptom Check List (HSCL), the Nottingham Health Profile (NHP), and the Psychological General Well-Being index. In addition, at the final examination the spouses completed a short questionnaire concerning their partner. Before treatment, the patients had lowered quality of life as determined by the HSCL and NHP inventories, and a correlation between the duration of GHD and the reported symptoms was observed. Upon treatment, the HSCL score was lower (better) after placebo administration (mean +/- SD, 84 +/- 21.3) than at baseline (89 +/- 18.9; P = NS) and fell to 80.2 +/- 18.5 (P < 0.001) when active drug was given. The subscales regarding anxiety, fearfulness, and cognition were the most sensitive. It was apparent that the effect determined after GH therapy in part was due to a placebo effect. With NHP, the dimensions of energy and emotions responded most to treatment. Further, the spouses observed their partners to be improved in several aspects of mood and behavior (P < 0.05 to P < 0.0001) when active drug was given. The data thus demonstrate that GH, which is known to have multiple somatic effects, produces an improvement in the quality of life of adults with GHD.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Cross-Over Studies, Double-Blind Method, Female, Growth Hormone/deficiency, Health Status, Humans, Male, Mental Health, Middle Aged, Placebos, Quality of Life, Recombinant Proteins, Surveys and Questionnaires, Treatment Outcome
in
The Journal of clinical endocrinology and metabolism
volume
80
issue
12
pages
90 - 3585
publisher
Oxford University Press
external identifiers
  • scopus:0028867595
  • pmid:8530603
ISSN
0021-972X
DOI
10.1210/jcem.80.12.8530603
language
English
LU publication?
no
id
1afdde74-566c-44ef-8c31-b59778306543
date added to LUP
2023-11-27 09:35:02
date last changed
2024-01-10 11:53:00
@article{1afdde74-566c-44ef-8c31-b59778306543,
  abstract     = {{<p>We examined the effect of GH supplementation on the psychological capacity and sense of well-being in 36 patients with adult-onset GH deficiency (GHD). Recombinant human GH was given in a 21-month cross-over, double blind trial, and quality of life was assessed by using three self-rating questionnaires: the Hopkins Symptom Check List (HSCL), the Nottingham Health Profile (NHP), and the Psychological General Well-Being index. In addition, at the final examination the spouses completed a short questionnaire concerning their partner. Before treatment, the patients had lowered quality of life as determined by the HSCL and NHP inventories, and a correlation between the duration of GHD and the reported symptoms was observed. Upon treatment, the HSCL score was lower (better) after placebo administration (mean +/- SD, 84 +/- 21.3) than at baseline (89 +/- 18.9; P = NS) and fell to 80.2 +/- 18.5 (P &lt; 0.001) when active drug was given. The subscales regarding anxiety, fearfulness, and cognition were the most sensitive. It was apparent that the effect determined after GH therapy in part was due to a placebo effect. With NHP, the dimensions of energy and emotions responded most to treatment. Further, the spouses observed their partners to be improved in several aspects of mood and behavior (P &lt; 0.05 to P &lt; 0.0001) when active drug was given. The data thus demonstrate that GH, which is known to have multiple somatic effects, produces an improvement in the quality of life of adults with GHD.</p>}},
  author       = {{Burman, P and Broman, J E and Hetta, J and Wiklund, I and Erfurth, E M and Hagg, E and Karlsson, F A}},
  issn         = {{0021-972X}},
  keywords     = {{Adult; Cross-Over Studies; Double-Blind Method; Female; Growth Hormone/deficiency; Health Status; Humans; Male; Mental Health; Middle Aged; Placebos; Quality of Life; Recombinant Proteins; Surveys and Questionnaires; Treatment Outcome}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{90--3585}},
  publisher    = {{Oxford University Press}},
  series       = {{The Journal of clinical endocrinology and metabolism}},
  title        = {{Quality of life in adults with growth hormone (GH) deficiency : response to treatment with recombinant human GH in a placebo-controlled 21-month trial}},
  url          = {{http://dx.doi.org/10.1210/jcem.80.12.8530603}},
  doi          = {{10.1210/jcem.80.12.8530603}},
  volume       = {{80}},
  year         = {{1995}},
}